Search results for: Scotland
Filter search results
The Tougher the Better: The Effect of an Increased Performance Threshold on the Performance of General Practitioners
4 January 2012
In April 2006, payment thresholds were raised for GPs who participate in Scotland’s Ouality and Outcomes Framework. GPs were required to meet new, higher thresholds on some indicators to receive…
Routine Funding in the UK NHS of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
18 December 2017
…Scotland, products used in oncology and orphan disease were associated with a lower odds of receiving a positive HTA recommendation compared with non-oncology products and products which did not receive…
Primary Care and the NHS Reforms: A Manager’s View
1 March 2000
…in particular. The third chapter examines the manner in which Wales, Scotland and Northern Ireland are taking forward the reforms. Significant variations from the English model are discernible, particularly in…
Published in Health Economics: the Effect of Free Personal Care for the Elderly on Informal Caregiving
17 March 2015
Just published in Health Economics is an article by OHE’s Sarah Karlsberg Schaffer that estimates the effect of free personal care on the supply of informal care. In Scotland, since…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
…in a selection of industrialised countries: Australia, Canada, France, Scotland, and the United Kingdom (England and Wales). The aims of the study are to identify the key determinants of decisions…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
…and coverage is limited. In Wales, Scotland and Northern Ireland, lack of hospital prescription data poses an important barrier for the assessment of medicine use by indication, with limited primary…
Future UK Medicines Spending: Four Nation Analysis
31 October 2012
…nations (England, Northern Ireland, Scotland and Wales). In July, OHE released projections for medicines spending in the UK NHS for 2012‒2015. We have now completed further projections, also for the…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…11, 2010. Accessed February 27, 2024. https://www.ohe.org/publications/assessment-impact-orphan-medicinal-products-european-economy-and-society/ Garau M. Recent Statistics on Orphan Approvals in Scotland and England – OHE. Office of Health Economics. Published August 22, 2011. Accessed February…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
…Denmark, Sweden and Scotland. Overall, 13 reimbursement decisions (six for entrectinib, seven for larotrectinib) with publicly accessible documents were analysed to understand the assessment outcomes and what evidence may have…